Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy
Authors:
- Christoph DanielCDChristoph Daniel
- Harald SchöcklmannHSHarald Schöcklmann
- Karl-Hans EndlichKEKarl-Hans Endlich
- Dontscho KerjaschkiDKDontscho Kerjaschki
- Richard J. JohnsonRJRichard J. Johnson
- Christian HugoCHChristian Hugo
Open Access
- 21 July 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 21 (10) , 2724-2735
Abstract
Background. Everolimus is a potent immunosupressant used in renal transplant therapy, but its effects on renal endothelial cell regeneration after injury are unknown. The effects of an everolimus therapy were investigated in a model of renal thrombotic microangiopathy (TMA) with specific endothelial cell (EC) injury in the rat in vivo as well as in glomerular ECs in vitro . Methods. During the early regenerative phase (day 3) of the renal microvascular injury model in vivo , everolimus inhibited glomerular EC proliferation by up to 60% compared with vehicle-treated rats, whereas apoptosis was not different in these groups. This decreased EC proliferation was associated with an enhanced deposition of fibrin in everolimus treated animals on day 3. In cultured glomerular endothelial cells, everolimus effectively and dose dependently inhibited cellular proliferation. This anti-proliferative effect was associated with a reduced phosphorylation of the p70S6 kinase and reduction of the pro-angiogenic factor VEGF in glomeruli in vivo and in cultured podocytes in vitro . Results. Despite the prolonged EC repair and in contrast to the anti-Thy1 nephritis model, everolimus therapy did not disturb the long-term repair reaction in this thrombotic microangiopathy model. Conclusion. Everolimus is anti-proliferative for glomerular EC in vitro and in vivo and does not seem to have detrimental long-term effects in experimental renal TMA, when only the glomerular endothelium, but not the mesangium is severely injured.Keywords
This publication has 42 references indexed in Scilit:
- VEGF induces proliferation, migration, and TGF-β1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinaseBiochemical and Biophysical Research Communications, 2005
- Sirolimus‐Induced Thrombotic Microangiopathy is Associated with Decreased Expression of Vascular Endothelial Growth Factor in KidneysAmerican Journal of Transplantation, 2005
- The Rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1Laboratory Investigation, 2004
- Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathiesNephrology Dialysis Transplantation, 2004
- The effect of combined rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats, compared with cyclosporine or rapamycin in isolationTransplant International, 2003
- Rapamycin is an effective inhibitor of human renal cancer metastasis11See Editorial by Sukhatme and Strom, p. 1160.Kidney International, 2003
- Integrin (α6β4) regulation of eIF-4E activity and VEGF translationJournal of Cell Biology, 2002
- Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injuryKidney International, 2000
- The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis.Journal of Clinical Investigation, 1996
- Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes.Journal of Cell Biology, 1993